AstraZeneca Pharma India Limited announced unaudited earnings results for the third quarter and nine months ended Dec. 31, 2017. For the quarter the company reported revenue from operations of INR 1,285.386 million compared to INR 1,515.022 million a year ago. Total revenue was INR 1,312.983 million compared to INR 1,613.999 million a year ago. Loss before exceptional and extraordinary items and tax was INR 118.161 million compared to profit of INR 210.022 million a year ago. Loss before tax was INR 118.161 million compared to profit of INR 210.022 million a year ago. Loss for the period was INR 103.522 million compared to profit of INR 162.104 million a year ago. Basic and diluted loss per share of INR 2 each was INR 4.14 compared to earnings per share of INR 6.48 a year ago. For the nine months, the company reported revenue from operations of INR 4,212.627 million compared to INR 4,317.737 million a year ago. Total revenue was INR 4,311.721 million compared to INR 4,451.711 million a year ago. Profit before exceptional and extraordinary items and tax was INR 297.436 million compared to INR 374.929 million a year ago. Profit before tax was INR 297.436 million compared to INR 374.929 million a year ago. Profit for the period was INR 226.937 million compared to INR 296.144 million a year ago. Basic and diluted earnings per share of INR 2 each was INR 9.08 compared to INR 11.85 a year ago.